ClinicalTrials.gg
CompletedNCT04039022Updated Oct 12, 2022Results posted

Open-Label Safety Study of AXS-05 in Subjects With Depression

A Phase 3 interventional study of AXS-05 (dextromethorphan and bupropion) oral tablets in Major Depressive Disorder, Treatment Resistant Depression and Depression, sponsored by Axsome Therapeutics, Inc.. Completed at 51 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-10-12.

Sponsored by Axsome Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
876
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc. — 2 open to participants now, 2 under way, 1 of them phase 3. Depressive Disorder, Major · Axsome Therapeutics, Inc..

Enrollment
Largest of 10
876 · median 320
Started
2019
with 1 other
Phase 3
5 of 10
1 open now
Registered
4th of 10
by date

Among the 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc., this one has the largest enrollment, is one of 2 that started in 2019, is one of 5 in phase 3, and was the 4th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

2 of the 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Depressive Disorder, Major by Axsome Therapeutics, Inc., or all of them as a file.
02

Study summary

An open-label, long-term, safety study of AXS-05 in patients with major depressive disorder (MDD), including treatment resistant depression.

Read the detailed description

A multi-center, open-label, long-term study to evaluate the safety and efficacy of AXS-05 in patients with major depressive disorder, including treatment resistant depression, treated for up to one year.

03

Conditions studied

  • Major Depressive Disorder
  • Treatment Resistant Depression
  • Depression

Keywords

  • Depression
  • AXS-05
  • Dextromethorphan
  • Bupropion
  • Dopamine Reuptake Inhibitor
  • NMDA Receptor Antagonist
  • Nicotinic Acetylcholine Receptor Antagonist
  • Serotonin Reuptake Inhibitor
  • Axsome Therapeutics
  • Norepinephrine Reuptake Inhibitor
  • Sigma-1 Receptor Agonist
  • Glutamate Modulator
  • Antidepressant
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of major depressive disorder, including treatment resistant depression
  • (BMI) between 18 and 40 kg/m\^2, inclusive
  • Agree to use adequate method of for the duration of the study
  • Additional criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Suicide risk
  • Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
  • Additional criteria may apply
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
876 participants (actual)

Study arms

  • Experimental
    AXS-05

    Drug: AXS-05 (dextromethorphan and bupropion) oral tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-emergent AEs (TEAEs) Following Dosing With AXS-05

    Types and rates of adverse events

    Time frame: Up to 12 months

07

Results

Posted Oct 12, 2022

Participant flow

Participant flow — Overall Study
MilestoneAXS-05
Started876
Completed53
Not completed823

Outcome measures

PrimaryIncidence of Treatment-emergent AEs (TEAEs) Following Dosing With AXS-05

Types and rates of adverse events

Time frame:
Up to 12 months
Reported as:
Count of participants · Participants
Incidence of Treatment-emergent AEs (TEAEs) Following Dosing With AXS-05
ParticipantsAXS-05
Incidence of Treatment-emergent AEs (TEAEs) Following Dosing With AXS-05505

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) were AEs with an onset date on or after the date of first dose. TEAEs were collected through 30 days after the last study visit.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AXS-052/876 (0.2%)21/876 (2.4%)609/876 (69.5%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventAXS-05
Acute myocardial infarctionCardiac disorders1/876
Coronary artery diseaseCardiac disorders1/876
Left ventricular hypertrophyCardiac disorders1/876
Eye inflammationEye disorders1/876
NauseaGastrointestinal disorders1/876
Chest painGeneral disorders1/876
DeathGeneral disorders1/876
CholelithiasisHepatobiliary disorders1/876
CellulitisInfections and infestations1/876
DiverticulitisInfections and infestations1/876
Most frequent other events
Showing 10 of 12
Most frequent other events
EventAXS-05
DizzinessNervous system disorders111/876
NauseaGastrointestinal disorders104/876
HeadacheNervous system disorders77/876
Dry mouthGastrointestinal disorders62/876
Decreased appetiteMetabolism and nutrition disorders53/876
NasopharyngitisInfections and infestations39/876
Upper respiratory tract infectionInfections and infestations35/876
AnxietyPsychiatric disorders34/876
DiarrheaGastrointestinal disorders33/876
InsomniaPsychiatric disorders31/876

Baseline characteristics

Overall Safety Population (all subjects who received at least 1 dose of AXS-05)

Age, Continuous
Age, Continuous(years)AXS-05
Mean42.5 ± 13.5
Sex: Female, Male
Sex: Female, Male(Participants)AXS-05
Female560
Male316
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AXS-05
American Indian or Alaska Native3
Asian29
Native Hawaiian or Other Pacific Islander4
Black or African American301
White509
More than one race10
Unknown or Not Reported20
08

Study locations

51 sites
  • Clinical Research Site
    Phoenix, Arizona 85012, United States
  • Clinical Research Site
    Little Rock, Arkansas 72209, United States
  • Clinical Research Site
    Bellflower, California 90706, United States
  • Clinical Research Site
    Beverly Hills, California 90210, United States
  • Clinical Research Site
    Culver City, California 90230, United States
  • Clinical Research Site
    Garden Grove, California 92845, United States
  • Clinical Research Site
    Oakland, California 94607, United States
  • Clinical Research Site
    Oceanside, California 92056, United States
  • Clinical Research Site
    Panorama City, California 91402, United States
  • Clinical Research Site
    Redlands, California 92374, United States
  • Clinical Research Site
    San Diego, California 92103, United States
  • Clinical Research Site
    Sherman Oaks, California 91403, United States
  • Clinical Research Site
    Upland, California 91786, United States
  • Clinical Research Site
    Cromwell, Connecticut 06416, United States
  • Clinical Research Site
    Coral Springs, Florida 33067, United States
  • Clinical Research Site
    Hialeah, Florida 33012, United States
  • Clinical Research Site
    Hollywood, Florida 33024, United States
  • Clinical Research Site
    Jacksonville, Florida 32256, United States
  • Clinical Research Site
    Lauderhill, Florida 33319, United States
  • Clinical Research Site
    Miami, Florida 33122, United States
  • Clinical Research Site
    North Miami, Florida 33161, United States
  • Clinical Research Site
    Orlando, Florida 32801, United States
  • Clinical Research Site
    Atlanta, Georgia 30328, United States
  • Clinical Research Site
    Atlanta, Georgia 30331, United States
  • Clinical Research Site
    Boise, Idaho 83704, United States
  • Clinical Research Site
    Chicago, Illinois 60634, United States
  • Clinical Research Site
    Boston, Massachusetts 02131, United States
  • Clinical Research Site
    Las Vegas, Nevada 89102, United States
  • Clinical Research Site
    Berlin, New Jersey 08009, United States
  • Clinical Research Site
    Cherry Hill, New Jersey 08002, United States
  • Clinical Research Site
    Toms River, New Jersey 08755, United States
  • Clinical Research Site
    Jamaica, New York 11432, United States
  • Clinical Research Site
    Rochester, New York 14618, United States
  • Clinical Research Site
    Staten Island, New York 10312, United States
  • Clinical Research Site
    Hickory, North Carolina 28601, United States
  • Clinical Research Site
    Raleigh, North Carolina 27609, United States
  • Clinical Research Site
    Cincinnati, Ohio 45215, United States
  • Clinical Research Site
    Cincinnati, Ohio 45219, United States
  • Clinical Research Site
    Middleburg Heights, Ohio 44130, United States
  • Clinical Research Site
    Oklahoma City, Oklahoma 73112, United States
  • Clinical Research Site
    Media, Pennsylvania 19063, United States
  • Clinical Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Clinical Research Site
    Memphis, Tennessee 38119, United States
  • Clinical Research Site
    Austin, Texas 78712, United States
  • Clinical Research Site
    Dallas, Texas 75243, United States
  • Clinical Research Site
    Fort Worth, Texas 76104, United States
  • Clinical Research Site
    Houston, Texas 77058, United States
  • Clinical Research Site
    San Antonio, Texas 78229, United States
  • Clinical Research Site
    Wichita Falls, Texas 76309, United States
  • Clinical Research Site
    Bellevue, Washington 98007, United States
  • Clinical Research Site
    Everett, Washington 98201, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Oct 2020, 15 months.

Results were first posted in Oct 2022, 1 year 11 months after primary completion. A results delay was requested in Oct 2021.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 15 months is below that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2019
First posted
Jul 31, 2019
StartActual
Jul 8, 2019
Primary completionActual
Oct 23, 2020
CompletionActual
Oct 23, 2020
Results delay requested
Oct 18, 2021
Results first posted
Oct 12, 2022
Last update
Oct 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04039022
Responsible party
Sponsor
First posted
Jul 31, 2019
Start date
Jul 8, 2019
Primary completion
Oct 23, 2020
Completion
Oct 23, 2020
Results posted
Oct 12, 2022
Last update
Oct 12, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dextromethorphan/Bupropion Tablet AXS-05

Start the discussion